Brief: Onco360 Selected By ADC Therapeutics To Be Exclusive Specialty Pharmacy Partner For ZYNLONTA
27/04/2021 16:09
April 27 (Reuters) - ONCO360:
* ONCO360 - SELECTED BY ADC THERAPEUTICS TO BE EXCLUSIVE
SPECIALTY
PHARMACY PARTNER FOR ZYNLONTA
Source text for Eikon: urn:newsml:reuters.com:*:nBw7FKKja
Further company coverage: ADCT.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ADC Therapeutics SA
See all newsADC Therapeutics plunges after patient deaths in blood cancer drug trial
ADC Therapeutics falls on higher rates of serious side-effects in cancer trial
Switzerland's ADC Therapeutics beats Q1 revenue estimates
Switzerland's ADC Therapeutics posts smaller‑than‑expected Q4 net loss on lower R&D spend
Brief: ADC Therapeutics Q4 Income From Operations USD -17.919 Million Vs. IBES Estimate USD -30.1 Million